Pharmacokinetic variability of extended interval tobramycin in burn patients

Burns

Volumn 34, Issue 6, 2008, Pages 791-796

  Bracco, David ^a   Landry, Christine ^a   Dubois, Marc Jacques ^a   Eggimann, Philippe ^b  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Aminoglycoside; Burn; Critically ill patients; Distribution volume; Nosocomial infection; Pharmacokinetics; Therapeutic drug monitoring; Tobramycin

Indexed keywords

TOBRAMYCIN;

ADULT; AGED; ARTICLE; BURN INFECTION; BURN PATIENT; CLINICAL ARTICLE; CLINICAL TRIAL; CREATININE CLEARANCE; CRITICALLY ILL PATIENT; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MEGADOSE; DRUG MONITORING; DRUG SURVEILLANCE PROGRAM; FEMALE; HOSPITAL INFECTION; HUMAN; INTENSIVE CARE UNIT; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; PROSPECTIVE STUDY; PSEUDOMONAS;

ADULT; AGED; ANTI-BACTERIAL AGENTS; BURNS; CREATININE; CRITICAL CARE; CRITICAL ILLNESS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; DRUG MONITORING; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PSEUDOMONAS INFECTIONS; TOBRAMYCIN; TREATMENT OUTCOME; WOUND INFECTION;

EID: 47649120860     PISSN: 03054179     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.burns.2007.11.003     Document Type: Article

References (17)

1. Weinbren M.J. Pharmacokinetics of antibiotics in burn patients. J Antimicrob Chemother 44 (1999) 319-327
2. Burton M.E., Ash C.L., Hill Jr. D.P., Handy T., Shepherd M.D., and Vasko M.R. A controlled trial of the cost benefit of computerized bayesian aminoglycoside administration. Clin Pharmacol Ther 49 (1991) 685-694
3. Vinks A.A., Evers N., Mathot R., and Michel B. Impact of goal-oriented model-based tdm of aminoglycosides on clinical outcome: a cost-effectiveness analysis. Ther Drug Monit 19 (1997) 547 [Abstract]
4. Conil J.M., Georges B., Breden A., Segonds C., Lavit M., Seguin T., et al. Increased amikacin dosage requirements in burn patients receiving a once-daily regimen. Int J Antimicrob Agents 28 (2006) 226-230
5. Barletta J.F., Johnson S.B., Nix D.E., Nix L.C., and Erstad B.L. Population pharmacokinetics of aminoglycosides in critically ill trauma patients on once-daily regimens. J Trauma 49 (2000) 869-872
6. Chicano-Pia P.V., Cercos-Lleti A.C., and Roma-Sanchez E. Pharmacokinetic model for tobramycin in acinetobacter meningitis. Ann Pharmacother 36 (2002) 83-86
7. Dorman T., Swoboda S., Zarfeshenfard F., Trentler B., and Lipsett P.A. Impact of altered aminoglycoside volume of distribution on the adequacy of a three milligram per kilogram loading dose. Critical care research group. Surgery 124 (1998) 73-78
8. Hoey L.L., Tschida S.J., Rotschafer J.C., Guay D.R., and Vance-Bryan K. Wide variation in single, daily-dose aminoglycoside pharmacokinetics in patients with burn injuries. J Burn Care Rehabil 18 (1997) 116-124
9. Ngui-Yen J.H., Doyle P.W., and Smith J.A. Comparative analysis of two rapid, automated methods for determining aminoglycoside levels. J Clin Microbiol 20 (1984) 962-965
10. Gilbert D.N., Moellering R.C., Ellopoulos G.M., and Sande M.A. The Sanford guide to antimicrobial therapy 2007. 37th ed. (2007), Antimicrobial Therapy Inc., P.O. Box 276, 11771 Lee Highway, Sperryville, VA 22740-0276, USA
11. Turnidge J. Pharmacodynamics and dosing of aminoglycosides. Infect Dis Clin North Am 17 (2003) 503-528
12. Bailey D.N., and Briggs J.R. Gentamicin and tobramycin binding to human serum in vitro. J Anal Toxicol 28 (2004) 187-189
13. Nagai J., and Takano M. Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity. Drug Metab Pharmacokinet 19 (2004) 159-170
14. Birn H., Fyfe J.C., Jacobsen C., Mounier F., Verroust P.J., Orskov H., et al. Cubilin is an albumin binding protein important for renal tubular albumin reabsorption. J Clin Invest 105 (2000) 1353-1361
15. Peris-Marti J.F., Borras-Blasco J., Rosique-Robles J.D., and Gonzalez-Delgado M. Evaluation of once daily tobramycin dosing in critically ill patients through Bayesian simulation. J Clin Pharm Ther 29 (2004) 65-70
16. Buijk S.E., Mouton J.W., Gyssens I.C., Verbrugh H.A., and Bruining H.A. Experience with a once-daily dosing program of aminoglycosides in critically ill patients. Intensive Care Med 28 (2002) 936-942
17. Tod M.M., Padoin C., and Petitjean O. Individualising aminoglycoside dosage regimens after therapeutic drug monitoring: simple or complex pharmacokinetic methods?. Clin Pharmacokinet 40 (2001) 803-814